Download a Free Sample To learn more about this report,
The United Kingdom Autoinjectors Market size was valued at USD 628 million in 2025 and is projected to grow from USD 678 million in 2026 to reach USD 1.32 billion by 2034, growing at a CAGR of 8.62% during the forecast period 2026–2034.
An autoinjector is a medical tool used to administer a certain amount of medication, usually by injection. It is made to be simple to use by the patient or caregiver. It often includes a pre-filled syringe, a needle, and a spring-loaded mechanism that releases the medication fast and easily with the push of a button. Common uses for autoinjectors include treating, among others, illnesses including allergies, arthritic, and multiple sclerosis. They can help lower the danger of unintentional needle stick injuries and are frequently utilized in emergency settings where quick drug administration is required.
The number of anaphylactic shock cases documented in the U.K. has noticeably increased. This increase can be ascribed to several things, such as increased allergies, environmental changes, and better reporting and knowledge of anaphylactic events. The U.K.'s National Health Service (NHS) has acknowledged the significance of immediately and successfully treating anaphylactic shock. As a result, there is a large demand for autoinjectors, particularly those that contain epinephrine (adrenaline). Epinephrine autoinjectors are frequently utilized as the first line of treatment to quickly treat symptoms of anaphylactic shock and avoid potentially fatal consequences.
The demand for autoinjectors has grown as a result of the rise in anaphylactic shock cases in the U.K. Pharmaceutical companies, like Mylan N.V. (now Viatris Inc.), the maker of the EpiPen, have been spurred by this trend to spend on R&D, ensuring the availability of cutting-edge autoinjector devices and enhancing patient outcomes.
Technology and new drug delivery methods have expanded patient medicine alternatives. In specific therapeutic areas, inhalers, transdermal patches, and oral drugs have become popular. Asthma and COPD patients prefer inhalers. Symptoms are quickly relieved with portable, convenient, and exact dosing inhalers. Inhalers may be preferable to autoinjectors for respiratory disorders. The autoinjectors market faces competition from alternative drug delivery methods.
Medical devices and pharmaceutical items are heavily regulated in the U.K. by the Medicines and Healthcare Products Regulatory Agency (MHRA). Before these items may be advertised and disseminated, the FDA ensures they adhere to safety, quality, and efficacy requirements. Streamlined regulatory rules can lessen the compliance burden on autoinjector producers, allowing them to market their goods more quickly and effectively. This may result in more innovation, rivalry, and autoinjector options for patients and healthcare professionals. The U.K. government has worked to simplify regulatory procedures in recent years to promote expansion and innovation in the healthcare sector. For instance, the MHRA has implemented programs like the Innovation Passport, which gives medical devices including autoinjectors that exhibit innovation and satisfy certain requirements a faster road.
The United Kingdom autoinjectors market is segmented based on therapy, type, and end-user.
The market is further segmented by therapy into Anaphylaxis, Rheumatoid Arthritis, Psoriasis, migraines, Cardiovascular-diseases, and others.
The Anaphylaxis segment dominates the market and is expected to grow at a CAGR of 19.4% during the forecast period.
The market is further segmented by type into Disposable, Reusable.
Disposable dominated the market and is expected to register a CAGR of 19.2% over the forecast period.
The market is further segmented by end-user into Hospitals and clinics, home care, and others.
The home care segment dominates the market and is expected to grow at a CAGR of 20.4% during the forecast period.
Request Customizationto receive a tailored report.
Speak to an Analystto discuss market opportunities.
The U.K. autoinjectors market will expand at the quickest rate due to the rising prevalence of anaphylaxis and the rising number of adrenaline autoinjectors (AAI) prescriptions. According to a study by NCBI, the incidence rate of anaphylaxis in the United Kingdom has risen sharply since 2012. The rate at which AAI is prescribed for each child is likewise increasing. Consequently, the U.K. autoinjectors market is anticipated to expand significantly throughout the predicted timeframe.
Growth in both areas will be sparked by introducing cutting-edge drug delivery methods and devices and attractive reimbursement policies for key companies.
Compared to other European countries, the U.K. has been shown to use diabetes pens extensively. The World Health Organization estimates that 60 million individuals in the European Region have diabetes, with people over 25 having a higher disease prevalence. A low population seeking treatment coupled with social stigma in some areas, poor awareness, and relatively limited access to healthcare facilities, particularly in developing countries, are a few obstacles that restrict the region's potential for growth.
Customize This Report to Match Your Strategic Objectives
Author's Details
Healthcare Lead
Debashree Bora is a strategic healthcare research professional with nearly eight years of hands on experience in market intelligence, encompassing primary research, secondary research, market estimation, and consulting engagements. She specializes in pharmaceutical, biotechnology, medical devices, healthcare services, clinical trials, and healthcare outsourcing sectors, providing actionable insights on evolving industry trends, regulatory landscapes, competitive dynamics, and market opportunities. Debashree’s research helps global clients evaluate market potential, identify growth opportunities, strengthen commercial strategies, and make informed business decisions.
Her work focuses on assessing treatment landscapes, outsourcing models, technology adoption, market access dynamics, regulatory developments, and competitive positioning across healthcare and life sciences industries. Debashree has consistently supported organizations in understanding market gaps, evaluating revenue potential, developing market entry strategies, and shaping expansion plans across complex and fast evolving healthcare markets.
With a strong analytical foundation and structured research approach, she excels at synthesizing large datasets, stakeholder inputs, and market signals into actionable insights that guide strategic decision making. Her healthcare expertise enables her to connect clinical, commercial, and operational developments with business opportunities, helping stakeholders anticipate shifts and capitalize on emerging growth areas. Debashree’s consulting oriented mindset and deep healthcare industry understanding make her a trusted advisor to businesses navigating dynamic and rapidly evolving healthcare markets.
Severity: Notice
Message: Undefined variable: relatedReports
Filename: reportpages/rd.php
Line Number: 640
Backtrace:
File: /var/www/html/application/views/frontend/reportpages/rd.php Line: 640 Function: _error_handler
File: /var/www/html/application/controllers/FrontendRegionalReportController.php Line: 108 Function: view
File: /var/www/html/index.php Line: 364 Function: require_once
We are featured on:
sales@straitsresearch.com